Successful treatment with rituximab for angioimmunoblastic T-cell lymphoma.
Leuk Res Rep
; 2(1): 36-8, 2013.
Article
en En
| MEDLINE
| ID: mdl-24371775
ABSTRACT
We experienced a patient with angioimmunoblastic T-cell lymphoma (AITL) without Epstein-Barr virus-positive B (EBV-B) cells at initial presentation who progressed to AITL with expansion of EBV-B cells at relapse. Based on the results of repeated biopsy, the patient was successfully treated with rituximab in combination with chemotherapy at relapse. A repeat biopsy may be necessary to determine the optimum therapeutic strategy at relapse, particularly for patients with suspected expansion of B cell and/or EBV-B cells. Although a recent report found no significant prognostic advantage of rituximab, it is one of the active drugs for selected patients with AITL.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
Leuk Res Rep
Año:
2013
Tipo del documento:
Article